Lisa Rojkjaer - Viracta Therapeutics Chief Officer

VIRXDelisted Stock  USD 0.03  0  7.38%   

Insider

Lisa Rojkjaer is Chief Officer of Viracta Therapeutics
Age 58
Phone858 400 8470
Webhttps://www.viracta.com

Lisa Rojkjaer Latest Insider Activity

Tracking and analyzing the buying and selling activities of Lisa Rojkjaer against Viracta Therapeutics pink sheet is an integral part of due diligence when investing in Viracta Therapeutics. Lisa Rojkjaer insider activity provides valuable insight into whether Viracta Therapeutics is net buyers or sellers over its current business cycle. Note, Viracta Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Viracta Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Viracta Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.572) % which means that it has lost $0.572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0867) %, meaning that it created substantial loss on money invested by shareholders. Viracta Therapeutics' management efficiency ratios could be used to measure how well Viracta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Viracta Therapeutics currently holds 25.56 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Viracta Therapeutics has a current ratio of 11.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Viracta Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Viracta Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viracta Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viracta to invest in growth at high rates of return. When we think about Viracta Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Hannah FryProtara Therapeutics
34
Thomas MDTrevi Therapeutics
72
CBE FMedsciBicycle Therapeutics
71
CPA CPAStoke Therapeutics
63
John MDVincerx Pharma
N/A
Dawn KalmarStoke Therapeutics
47
Keith MDX4 Pharmaceuticals
54
Shinyu MDIGM Biosciences
55
Heow TanBiomea Fusion
66
Demetrios MDInozyme Pharma
N/A
Arthur TaverasX4 Pharmaceuticals
61
Mark OMahonyLeap Therapeutics
54
Saptarsi MDTenaya Therapeutics
N/A
Isabel AznarezStoke Therapeutics
52
Phil JDMonte Rosa Therapeutics
45
JD MBAMonte Rosa Therapeutics
46
Anup MBACabaletta Bio
48
Jason CavalierLyra Therapeutics
51
Christian HeinisBicycle Therapeutics
N/A
Melissa SPHRVincerx Pharma
N/A
John LewickiMereo BioPharma Group
73
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. Viracta Therapeutics [VIRX] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading. Viracta Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Viracta Therapeutics Leadership Team

Elected by the shareholders, the Viracta Therapeutics' board of directors comprises two types of representatives: Viracta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viracta. The board's role is to monitor Viracta Therapeutics' management team and ensure that shareholders' interests are well served. Viracta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viracta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel CPA, COO, CFO
Cheryl Madsen, Senior Affairs
Daniel Chevallard, COO CFO
Thalia MD, CoFounder
Patric MBA, Senior Strategy
Ronald MD, CoFounder Consultant
George Hillman, CoFounder
Robert Williams, CoFounder
Robert McRae, Vice Alliances
Ayman ElGuindy, Chief Officer
Mark Rothera, President CEO
Stewart Brown, Senior Counsel
Susan MD, Scientific Consultant
Michael Faerm, Chief Officer
Lisa Rojkjaer, Chief Officer
Biljana PharmD, Senior Development

Viracta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Viracta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Consideration for investing in Viracta Pink Sheet

If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Share Portfolio
Track or share privately all of your investments from the convenience of any device